Bionor Pharma – Final result of the rights issue
(Oslo, Norway, 4 October 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).
BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG
KONG OR THE UNITED STATES
The subscription period for the Rights Issue ended on 29 September 2016 at 16.30 CET. At the end of the subscription period, Bionor had received subscriptions for a total of 1,143,981,455 new shares, corresponding to an oversubscription of 117.9%.
Allocation of 525,000,000 new shares in the Rights Issue was approved by the Board of Directors on 4 October 2016. The Rights Issue raised gross proceeds of NOK 52.5 million.
The Board of Directors of Bionor Pharma ASA has approved the final allocation of the shares subscribed in the Rights Issue based on the allocation criteria set out in the Prospectus. A total of 469.2 million new shares have been allocated to subscribers on the basis of exercised subscription rights and 55.8 million shares have been allocated to holders of subscription rights as a result of oversubscription. No shares have been allocated to subscribers without subscription rights.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Unni Hjelmaas, Acting CEO, +47 915 19 651, email@example.com
Jens Krøis, CFO, +45 208 01 668, firstname.lastname@example.org
Link to announcement in pdf